Company Interview / Orthocell's US debut sparks record revenue

Orthocell (ASX:OCC) announces the first surgical use of its groundbreaking nerve repair product in the US, achieving a record $2.7 million in revenue for the June quarter. Paul Anderson MD and CEO of Orthocell states the revenue rise is driven by product demand.

Paul comments that Orthocell sees great potential in the $1.6 billion US nerve repair market, given the high number of nerve repairs annually. By expanding their distribution network, they aim to leverage their FDA-approved product's success in Australia to the US market.

Paul highlights their strategy of direct engagement with surgeons and centres of excellence as key to market growth. With 14 distributors and over 100 representatives in 21 states, Orthocell (ASX:OCC) positions itself strongly, bolstered by a robust balance sheet of $28.5 million.